---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-007532"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T20:53:30.118876+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board

## Summary
- Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.
- Barbara Klencke, M.D. and Chris Takimoto, M.D., Ph.D. appointed to Board effective Jan 18, 2025; each receives initial option for 40,400 shares.
- Shantharam previously CFO of CymaBay ($4.3B Gilead acquisition); held finance roles at Gilead and Amgen.
- Klencke serves on boards of Xencor, TScan, Immune-Onc; Takimoto is CMO at START Center, former CMO at Forty Seven ($4.9B Gilead acquisition).
- Board expanded to 6 members; new committee assignments: Klencke on Audit/R&D, Takimoto on Compensation/R&D.

## SEC filing metadata
- accession: 0000950170-25-007532
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/alxo-20250116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-007532
- JSON: https://secwatch.observer/filing/0000950170-25-007532.json
- Plain text: https://secwatch.observer/filing/0000950170-25-007532.txt

## Key facts
- Executive change
  Barbara Klencke was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Director
  source text: Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm
- Executive change
  Shelly Pinto resigned as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: Interim Chief Financial Officer
  source text: Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm
- Executive change
  Chris Takimoto was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Director
  source text: and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm
- Executive change
  Harish Shantharam was appointed as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.